mitoxantrone has been researched along with Soft Tissue Neoplasms in 10 studies
Mitoxantrone: An anthracenedione-derived antineoplastic agent.
mitoxantrone : A dihydroxyanthraquinone that is 1,4-dihydroxy-9,10-anthraquinone which is substituted by 6-hydroxy-1,4-diazahexyl groups at positions 5 and 8.
Soft Tissue Neoplasms: Neoplasms of whatever cell type or origin, occurring in the extraskeletal connective tissue framework of the body including the organs of locomotion and their various component structures, such as nerves, blood vessels, lymphatics, etc.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The purpose of this study was to determine the maximum-tolerated dose of gemcitabine plus mitoxantrone in women with metastatic breast cancer (MBC) and to evaluate activity and toxicity of this combination in a phase II trial." | 9.10 | Phase I/II study of gemcitabine plus mitoxantrone as salvage chemotherapy in metastatic breast cancer. ( Calabrese, P; Caporusso, L; Catino, A; Crucitta, E; D'Amico, C; De Lena, M; Guida, M; Latorre, A; Lorusso, V; Mazzei, A; Sambiasi, D; Schittulli, F; Silvestris, N, 2003) |
| "The purpose of this study was to compare the activity and toxicity of epirubicin-vindesine (EV) with mitoxantrone-vindesine (MV) in patients with metastatic breast cancer." | 9.08 | Randomised phase II study of epirubicin-vindesine versus mitoxantrone-vindesine in metastatic breast cancer. ( Fridrik, M; Hausmaninger, H; Hehenwarter, W; Lehnert, M; Manfreda, D; Samonigg, H; Schiller, L; Sevelda, P; Steger, G; Tschurtschenthaler, G, 1995) |
| "Grade 3/4 neutropenia was observed in 29 patients (58%) with four neutropenic episodes." | 6.69 | First-line treatment of metastatic breast cancer with mitoxantrone, vinorelbine, and carboplatin. ( Agelaki, S; Androulakis, N; Georgoulias, V; Hatzidaki, D; Kakolyris, S; Koukourakis, M; Kourousis, C; Samonis, G; Tsiftsis, D; Vamvakas, L, 1999) |
| "Metastatic breast cancer remains an incurable disease and the median overall survival has not significantly improved over the past two decades." | 6.69 | Is salvage chemotherapy for metastatic breast cancer always effective and well tolerated? A phase II randomized trial of vinorelbine versus 5-fluorouracil plus leucovorin versus combination of mitoxantrone, 5-fluorouracil plus leucovorin. ( Comandini, D; Fusco, V; Merlini, L; Naso, C; Palumbo, R; Porcile, G; Pronzato, P; Repetto, L; Rosso, R; Simoni, C; Venturino, A, 2000) |
| "The purpose of this study was to determine the maximum-tolerated dose of gemcitabine plus mitoxantrone in women with metastatic breast cancer (MBC) and to evaluate activity and toxicity of this combination in a phase II trial." | 5.10 | Phase I/II study of gemcitabine plus mitoxantrone as salvage chemotherapy in metastatic breast cancer. ( Calabrese, P; Caporusso, L; Catino, A; Crucitta, E; D'Amico, C; De Lena, M; Guida, M; Latorre, A; Lorusso, V; Mazzei, A; Sambiasi, D; Schittulli, F; Silvestris, N, 2003) |
| "The purpose of this study was to compare the activity and toxicity of epirubicin-vindesine (EV) with mitoxantrone-vindesine (MV) in patients with metastatic breast cancer." | 5.08 | Randomised phase II study of epirubicin-vindesine versus mitoxantrone-vindesine in metastatic breast cancer. ( Fridrik, M; Hausmaninger, H; Hehenwarter, W; Lehnert, M; Manfreda, D; Samonigg, H; Schiller, L; Sevelda, P; Steger, G; Tschurtschenthaler, G, 1995) |
| "Grade 3/4 neutropenia was observed in 29 patients (58%) with four neutropenic episodes." | 2.69 | First-line treatment of metastatic breast cancer with mitoxantrone, vinorelbine, and carboplatin. ( Agelaki, S; Androulakis, N; Georgoulias, V; Hatzidaki, D; Kakolyris, S; Koukourakis, M; Kourousis, C; Samonis, G; Tsiftsis, D; Vamvakas, L, 1999) |
| "Metastatic breast cancer remains an incurable disease and the median overall survival has not significantly improved over the past two decades." | 2.69 | Is salvage chemotherapy for metastatic breast cancer always effective and well tolerated? A phase II randomized trial of vinorelbine versus 5-fluorouracil plus leucovorin versus combination of mitoxantrone, 5-fluorouracil plus leucovorin. ( Comandini, D; Fusco, V; Merlini, L; Naso, C; Palumbo, R; Porcile, G; Pronzato, P; Repetto, L; Rosso, R; Simoni, C; Venturino, A, 2000) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (20.00) | 18.7374 |
| 1990's | 4 (40.00) | 18.2507 |
| 2000's | 4 (40.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lorusso, V | 1 |
| Crucitta, E | 1 |
| Silvestris, N | 1 |
| Catino, A | 1 |
| Caporusso, L | 1 |
| Mazzei, A | 1 |
| Guida, M | 1 |
| Latorre, A | 1 |
| Sambiasi, D | 1 |
| D'Amico, C | 1 |
| Schittulli, F | 1 |
| Calabrese, P | 1 |
| De Lena, M | 1 |
| Presant, CA | 1 |
| Gams, R | 1 |
| Bartolucci, AA | 1 |
| Grönemeyer, DH | 1 |
| Seibel, RM | 1 |
| Ogilvie, GK | 1 |
| Straw, RC | 1 |
| Jameson, VJ | 1 |
| Walters, LM | 1 |
| Lafferty, MH | 1 |
| Powers, BE | 1 |
| Withrow, SJ | 1 |
| Hausmaninger, H | 1 |
| Lehnert, M | 1 |
| Steger, G | 1 |
| Sevelda, P | 1 |
| Tschurtschenthaler, G | 1 |
| Hehenwarter, W | 1 |
| Fridrik, M | 1 |
| Samonigg, H | 1 |
| Schiller, L | 1 |
| Manfreda, D | 1 |
| Kakolyris, S | 1 |
| Kourousis, C | 1 |
| Koukourakis, M | 1 |
| Androulakis, N | 1 |
| Vamvakas, L | 1 |
| Agelaki, S | 1 |
| Hatzidaki, D | 1 |
| Samonis, G | 1 |
| Tsiftsis, D | 1 |
| Georgoulias, V | 1 |
| Bashey, A | 1 |
| Corringham, S | 1 |
| Garrett, J | 1 |
| Lane, TA | 1 |
| Gilpin, EA | 1 |
| Corringham, RE | 1 |
| Law, P | 1 |
| Ho, AD | 1 |
| Breidenbach, M | 1 |
| Rein, D | 1 |
| Schmidt, T | 1 |
| Heindel, W | 1 |
| Kolhagen, H | 1 |
| Mallmann, P | 1 |
| Kurbacher, CM | 1 |
| Venturino, A | 1 |
| Comandini, D | 1 |
| Simoni, C | 1 |
| Merlini, L | 1 |
| Naso, C | 1 |
| Palumbo, R | 1 |
| Fusco, V | 1 |
| Porcile, G | 1 |
| Pronzato, P | 1 |
| Rosso, R | 1 |
| Repetto, L | 1 |
| Bull, FE | 1 |
| Von Hoff, DD | 1 |
| Balcerzak, SP | 1 |
| Stephens, RL | 1 |
| Panettiere, FJ | 1 |
6 trials available for mitoxantrone and Soft Tissue Neoplasms
| Article | Year |
|---|---|
Phase I/II study of gemcitabine plus mitoxantrone as salvage chemotherapy in metastatic breast cancer.
Topics: Adult; Aged; Bone Neoplasms; Breast Neoplasms; Deoxycytidine; Dose-Response Relationship, Drug; Drug | 2003 |
Randomised phase II study of epirubicin-vindesine versus mitoxantrone-vindesine in metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Diges | 1995 |
First-line treatment of metastatic breast cancer with mitoxantrone, vinorelbine, and carboplatin.
Topics: Adult; Aged; Alopecia; Anemia; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplas | 1999 |
A phase II study of two cycles of high-dose chemotherapy with autologous stem cell support in patients with metastatic breast cancer who meet eligibility criteria for a single cycle.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Carboplatin | 2000 |
Is salvage chemotherapy for metastatic breast cancer always effective and well tolerated? A phase II randomized trial of vinorelbine versus 5-fluorouracil plus leucovorin versus combination of mitoxantrone, 5-fluorouracil plus leucovorin.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Femal | 2000 |
Phase II trial of mitoxantrone in advanced sarcomas: a Southwest Oncology Group study.
Topics: Adolescent; Adult; Aged; Anthraquinones; Antineoplastic Agents; Bone Neoplasms; Clinical Trials as T | 1985 |
4 other studies available for mitoxantrone and Soft Tissue Neoplasms
| Article | Year |
|---|---|
Treatment of metastatic sarcomas with mitoxantrone.
Topics: Agranulocytosis; Anthraquinones; Antineoplastic Agents; Bone Neoplasms; Drug Evaluation; Female; Hum | 1984 |
[Microinvasive CT-controlled tumor therapy of soft tissue and skeletal metastases].
Topics: Adult; Aged; Aged, 80 and over; Bone Neoplasms; Combined Modality Therapy; Ethanol; Female; Humans; | 1993 |
Evaluation of single-agent chemotherapy for treatment of clinically evident osteosarcoma metastases in dogs: 45 cases (1987-1991).
Topics: Animals; Antineoplastic Agents; Bone Neoplasms; Chemotherapy, Adjuvant; Cisplatin; Dog Diseases; Dog | 1993 |
Intra-arterial mitoxantrone and paclitaxel in a patient with Stewart-Treves syndrome: selection of chemotherapy by an ex vivo ATP-based chemosensitivity assay.
Topics: Adenosine Triphosphate; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carc | 2000 |